SCHEMBL4025469

SCHEMBL4025469

O=C1CNC(=O)N1c1ccc(S(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
MAPK1 P28482 2/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
AR P10275 1/20 0.51
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
IGF1R P08069 2/20 0.38
GAA P10253 1/20 0.37
ALDH1A1 P00352 2/20 0.37
PTPRZ1 P23471 1/20 0.36
KIF11 P52732 2/20 0.36
RECQL P46063 2/20 0.35
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TYK2 P29597 1/20 0.35
POLB P06746 2/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11022463 0.79 AR (0.44) LMNASMN1; SMN2ARCA12CA1
SCHEMBL5906374 0.77 AR (0.60) ARCA12CA2CA9GAA
SCHEMBL1421707 0.74 AR (0.57) MAPK1HTTARGAAALDH1A1
SCHEMBL6173519 0.73 AR (0.52) ARGAARECQLMAPTL3MBTL1
SCHEMBL2932244 0.73 AR (0.52) ARIGF1RGAAALDH1A1PTPRZ1
SCHEMBL31308818 0.71 LMNA (0.93) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL17893648 0.71 LMNA (0.73) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL4427332 0.71 LMNA (0.73) LMNAMAPK1HTTSMN1; SMN2ALDH1A1
SCHEMBL853440 0.71 AR (0.49) LMNAMAPK1HTTSMN1; SMN2AR
SCHEMBL5302868 0.71 FAAH (0.50) SMN1; SMN2ARCA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281641-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS GENZYME CORPORATION 2017-10-05 US disclosed
EP-2035408-A1 SULPHUR-CONTAINING CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2009-03-18 EP disclosed
WO-2008000922-A1 SULPHUR-CONTAINING CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281641-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS NGF, NTRK1, TK1 LMNA 4219/4885MAPK1 226/4885HTT 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.